FierceBiotech

This blood cancer drug holds potential to control dangerous immune overreaction in COVID-19 patients, but the company declines to provide it for a clinical trial by Fred Hutch to validate the idea.

Fred Hutch researchers tout Iclusig's potential to tame cytokine storm in COVID but can't get Takeda on board Researchers in Seattle have uncovered an FDA-approved drug that may be effective in combating the cytokine storms that can plague those infected with COVID-19. But Takeda will not supply Iclusig for use in trials.